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Abstract
The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired
regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease
currently represents the most important prognostic indicator, which drives treatment algorithms, which include allo-
geneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as
soon as possible, whereas in standard-risk patients this procedure should be avoided also in light of related toxicity
and because there are no significant benefits. Furthermore, better characterization of the molecular genetic events can
drive therapeutic decisions: a historical example in this respect is represented by the use of tyrosine kinase inhibitors
(TKIs) in Philadelphia chromosome-positive ALL; in the upcoming future, TKIs might be used also in other subgroups,
such as breakpoint cluster region/Abelson 1-like cases and others with deregulated tyrosine kinases. Finally, the
greatest progress is currently achieved with new immunotherapies targeting frequently expressed surface antigens in
ALL. It is also a new chance for elderly ALL patients, so far spared from intensive chemotherapy and allo-SCT. These
targeted therapies will substantially change this treatment algorithm and the great challenge is to find optimal
sequence of the extended therapy options in an individual patient.
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In children, the cure rate is now 80%. Despite using the same
drugs, in adults the cure rate is lower, because of a higher risk
profile, chemoresistance, and increased toxicity. In 10 published
studies up to 2013 the cure rate was 35%. This changed in the
recent years: a cure rate of 50% to 60%, even higher in certain
subgroups, is obtained. Reasons for improvement are better risk
stratification, comprising conventional and genetic classification
factors and evaluation of minimal residual disease (MRD). Alloge-
neic (allo-) stem cell transplantation (SCT) contributed. In Phila-
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https://doi.org/10.1016/j.clml.2018.03.014(ALL)—the poorest prognostic subtype—the application of tyrosine
kinase inhibitors (TKIs) has improved the survival to 60%.
Nowadays, patients remaining MRDþ after induction therapy have
the worse outcome.
Immunotherapeutic approaches have been successfully explored
in ALL. B-lineage ALL blasts express surface antigens effectively
targeted by monoclonal antibodies: rituximab for CD20, inotuzu-
mab ozogamicin for CD22, and blinatumomab for CD19. These
immunotherapies improved outcome in relapsed/refractory (R/R)
and MRDþ ALL patients and are currently explored in first-line
disease. A new option is represented by chimeric antigen receptor
(CAR), targeting CD19; novel CAR generations, targeting CD22,
or CD19 and CD22, are under way.
They will substantially change treatment algorithms, implying
reduction of chemotherapy-intensity, thus permitting management
also of elderly patients, and reduced allocation to allo-SCT. This re-
view will focus on the achievement and integration of these targeted
therapies and how the treatment paradigms for ALL will change.Diagnosis
The diagnosis of ALL relies on different steps.Clinical Lymphoma, Myeloma & Leukemia May 2018 - 301
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Treatment of ALLCytomorphology. Cytomorphology must be evaluated for differ-
ential diagnosis with acute myeloid leukemia (AML). The French-
American-British (FAB) classification previously distinguished
3 FAB subtypes: FAB1 and FAB2 are not used anymore whereas a
FAB3 is almost invariably associated with a mature B-lineage ALL.
Flow Cytometry. Immunophenotyping using multichannel flow
cytometry (MFC) is crucial for ALL diagnosis, detection, and
monitoring of MRD, and potential targeted therapy. Recently,
novel MFC techniques have been developed by the EuroFlow
consortium to ensure accurate methodologies and to increase
sensitivity.1,2
B-Lineage ALL. Of the different types of ALL75% to 80%are of B-
cell lineage. The markers for B-lineage diagnosis are CD19, CD20,
CD22, CD24, and CD79a. Four differentiation stages are recognized
(see Table 1, B-lineage ALL). In 38% of patients, an aberrant coex-
pression of myeloid markers is detected.3 Although there is no striking
correlation between immunophenotype and well established cytoge-
netic subsets, a pro-B stage is often associated with t(4;11)/mixed-
lineage-leukemia (MLL) (alias lysine methyltransferase 2A) rear-
rangements (MLL-r), and a pre-B with t(1;19)/transcription factor 3
(TCF3)-PBX homeobox 1 (PBX1) rearrangements.4 Neuron-glial
antigen 2 (NG2) is detected in t(4;11)þ cases5 and CD66c has been
associated with Phþ ALL.6
T-Lineage ALL. T-lineage ALL represents 20% to 25% of ALL.
Crucial markers are CD1a, CD2, CD3 (surface as well as cyto-
plasm), CD4, CD5, CD7, and CD8: its diagnosis relies on CD3
surface/cytoplasmic expression. CD34 and myeloid antigens CD13
and/or CD33 can be expressed (34% and 24%, respectively).3
According to the stage of differentiation, 4 T-ALL subtypes
can be identified (Table 1, T-lineage ALL). The so-called early
T-precursor (ETP)-ALL was included in the most recent World
Health Organization classification7: it lacks CD1a and CD8
expression, has weak CD5 expression, and at least 1 myeloid and/or
stem cell marker and is discussed separately.8
Conventional Cytogenetics. In B-lineage ALL, several lesions with
prognostic significance were identified using conventional
karyotyping.Table 1 Immunophenotypic Characterization of B-Lineage ALL
B-Lineage ALL TdT CD19 CD79 cC
Pro-B þ þ þ
Common þ þ þ
Pre-B þ þ þ
B-mature  þ þ
T-Lineage ALL TdT cCD3 CD7 C
Pro-T þ þ þ
Pre-T þ þ þ
T-cortical þ þ þ
T-mature þ/ þ þ
Abbreviations: ALL ¼ acute lymphoblastic leukemia; cCD ¼ cytosplasmic CD; cIGm ¼
k/l; TdT ¼ terminaldeoxytrasnsferase.
Clinical Lymphoma, Myeloma & Leukemia May 2018Good prognosis aberrations include t(12;21)/ETS variant 6
(ETV6)-Runt related transcription factor 1 (RUNX1) and high
hyperdiploidy (51-65 chromosomes).
Aberrations associated with an intermediate risk comprise the
normal diploid subset, isolated trisomy 21, trisomy 8, del(6q), and
t(1;19)/TCF3-PBX1: in the latter, the dismal outcome is overcome
by the current therapeutic approaches.9 Furthermore, intra-
chromosomal amplification of chromoosme 21, defined as a
consistent amplification of the RUNX1 locus deriving from a
massive chromothripsis and identified in 2% of cases, was regarded
as a poor prognostic aberration: its prognostic effect might vary
according to treatment intensity.10 Translocations involving the
immunoglobulin heavy locus (IGH) locus recognize different fusion
partners, the most frequent being cytokine receptor like factor 2
(CRLF2), and CCAAT/enhancer binding protein genes and in-
hibitor of DNA binding 4, HLH protein.11
Poor prognostic aberrations are represented by MLL-r, mono-
somy 7, hypodiploidy/low hypodiploidy (and the related
near-triploid), and t(17;19)/TCF3-HLF, PAR BZIP transcription
factor.12 Patients with t(9;22)/breakpoint cluster region (BCR)-
Abelson (ABL1) rearrangements/fluorescent in situ hybridization-
amplified (Phþ) were considered the worse subgroup, but this
does not hold true in the TKI era.13
In T-lineage ALL,14 cytogenetic aberrations involve 14q11
breakpoints (t(10;14), t(11;14), t(1;14), etc). The t(8;14), involving
q24;q11, is associated with an aggressive presentation.15
Copy Number Aberrations. Genome-wide technologies identified
novel lesions.16 The most frequent is the Ikaros (IKZF1) deletion
(DIKZF1),17,18 identified in approximately 80% of cases with Phþ
ALL and in approximately 30% of B-lineage ALL lacking Ph
chromosome, in children as well as adults, with a higher incidence
in adults. Whereas DIKZF1 have prognostic significance in Ph
ALL pediatric cases, their role is more controversial in adult ALL: it
is emerging that their effect is limited to cases with additional
genomic lesions, particularly cyclin dependent kinase inhibitor 2A
and 2B (CDKN2A/B) and paired box 5.
CDKN2A/B deletions are identified in 40% of cases, and nega-
tively influence outcome in Phþ as well as Ph ALL; similar results
were reported for early B cell factor 1 (EBF1) deletions, detected inD22 CD10 cIgm sIgm sk/l
þ    
þ þ   
þ þ/ þ  
þ  þ þ þ
D2 CD5 CD1a sCD3 g/d or a/b
    
þ þ   
þ þ þ þ/ 
þ þ  þ þ/
cytoplasmic IG m; sCD ¼ surface CD; sIgm ¼ surface IG m; sk/l ¼ surface
Sabina Chiaretti et alapproximately 10% of adult patients, and RB transcriptional core-
pressor 1 deletions.19,20
Gene Mutations and Rearrangements in B-Lineage and T-ALL.
Regarding genome-wide sequencing identified novel mutations and
rearrangements: the most frequent involve the RAS pathway (KRAS
proto-oncogene, GTPase/NRAS proto-oncogene, GTPase [N/K
RAS], Fms related tyrosine kinase 3 (FLT3), protein tyrosine
phosphatase, non-receptor type 11 (PTPN11), neurofibromin 1
(NF1), and B-raf proto-oncogene, serine/threonine kinase muta-
tions), detected in>40%, prevailing in the hyperdiploid and MLL-r
cases and increasing at relapse.21
More rare mutations affect the Janus kinase (JAK)/signal trans-
ducer and activator of transcription (STAT) pathway (ie, JAK1/2,
JAK3 [in T-ALL], interleukin 7 receptor [IL7R], rarely CRLF2
mutations, SH2B adaptor protein 3 and interleukin 2 receptor
subunit beta. JAK/STAT mutations are frequent in BCR/ABL1-like
ALL and cases with IGH translocations.21
The RAS as well as the JAK/STAT pathway mutations are
detected in B- and T-lineage ALL.
Fusion genes involving tyrosine kinases are found, mostly in the
BCR/ABL1-like ALL cases; other novel fusion genes include MEF2D,
double homeobox, 4, ERG, ETS transcription factor, and CRLF2.22,23
In T-ALL, Notch1/F-box and WD repeat domain containing 7
lesions represent a frequent event (approximately 60%); JAK/STAT
and RAS pathway mutations can be detected, with a variable fre-
quency depending on the cohorts (10%-30%). Their recognition is
important because they have prognostic and therapeutic
implications.24
Prognostic Factors and Risk Stratification
Identification of prognostic parameters at diagnosis—including
age, white blood cell count, specific immunophenotypes and cyto-
genetic/genetic aberrations—allow patients’ stratification into risk
groups: standard-risk (SR) patients, with a good chance of cureTable 2 Prognostic Risk Factors
Risk Factor Risk Subset
Patient-Related
Age 40/55/65
Performance status >1
Disease-Related
WBC >30,000  109/L in B-lineage ALL
>100,000  109/L in T-lineage ALL
Phenotype Pro-B/Pro-T/ETP/mature T-ALL
Cytogenetics BCR-ABL1þ/MLLþ/BCR-ABL1þ
Genetics BCR/ABL1-like, CDKN2A/B, EBF1
Response to Therapy
Corticosteroid sensitivity
(blast count after pre-phase)
Poor prednisone response
(1  10 9/L)
Early blast cell response (BM
morphology)
>5% day 8, day 15
Time to CR (number of courses) >1 cycle
MRD MRD positivity (postinduction)
Abbreviations: ALL ¼ acute lymphoblastic leukemia; ETP ¼ early T-precursor; BM ¼ bone
marrow; MRD ¼ minimal residual disease; WBC ¼ white blood cell.using chemotherapy, and high-risk (HR) patients with one or more
risk factors. HR patients are most often candidates for allo-SCT in
first complete remission (CR; Table 2).25 Currently, MRD is
regarded as the most important prognostic factor.
Minimal Residual Disease Assessment, Terminology, and
Effect on Outcome
Minimal residual disease is the detection, using flow cytometry
(FCM) or molecular analysis, of residual leukemic cells. MRD
evaluation must be performed at the end of induction for treatment
intensification and during consolidation because MRD persistence/
reappearance (>104) can drive therapeutic decisions.
Minimal residual disease techniques must be sensitive (104),
applicable, reliable, and affordable: the most common are FCM,
polymerase chain reaction (PCR) analysis of rearranged immuno-
globulin and T-cell receptor (allele-specific oligonucleotide [ASO]-
PCR) genes, and real-time quantitative and polymerase chain reac-
tion (RQ-RT-PCR) methods for fusion genes, if present.26 FCM is
less sensitive than ASO-PCR and RQ-RT-PCR, mostly when 4- and
6-color are used; ASO-PCR represents the most reliable approach,
but it is time-consuming; finally, RQ-RT-PCR is highly sensitive
(104-106) and easy to perform; however, full standardization of all
steps and international quality assurance systems are not yet available.
Intensive research is ongoing to validate novel tools, such as next-
generation sequencing27 and digital droplet PCR.28
Minimal residual disease terminology is summarized in Table 3.29
Achievement of molecular complete molecular remission (CMR)
represents currently the most relevant independent prognostic factor
for disease-free survival (DFS) and overall survival (OS), as shown in
a meta-analysis of >13,000 patients (children and adults) with
ALL.30 Patients in CMR after induction had significantly superior
outcome, with a DFS of 54% to 74%, compared with 17% to 40%
for MRD-positive patients. Patients with molecular failure after
induction should proceed to a targeted therapy to reduce the tumor
load followed by an allo-SCT.31
Will MRD Evaluation Replace Pretherapeutic Risk Factors?. The
question is whether MRD evaluation overcomes the diagnostic risk
factors or they should be integrated. A practical approach is to enter
the conventional prognostic factors and MRD into a decision al-
gorithm. Thereby, SR patients in CMR (approximately 90%-95%),
will remain as such, whereas those who are MRDþ will be shifted to
HR. Clinically defined HR patients are potential candidates for allo-
SCT in first CR (CR1): it is not clear how to proceed if they achieve
a CMR, because some studies suggest no benefit from allo-SCT.
If MRD is not available, stratification should rely on diagnostic
clinical factors.
Unfortunately, 20% to 30% of adult ALL patients who are
MRD after induction will relapse. Reasons include loss of sensi-
tivity, clonal/subclonal evolution, extramedullary relapse, different
CD19 escape mechanisms, and others.29
Treatment Principles
Pre-Phase Therapy. In ALL, treatment should start immediately,
with a pre-phase—which represents the timing for diagnostic
workup—consisting of corticosteroids, sometimes in combination
with vincristine or cyclophosphamide.Clinical Lymphoma, Myeloma & Leukemia May 2018 - 303
Table 3 Response Parameters According to MRD
Terminology Definition
Complete (Hematologic) Remission Leukemic cells not detectable using light microscopy (<5% blast cells in bone marrow)
Complete Molecular Remission, MRD-Negativity Patient in complete remission, MRD not detectable, 0.01% ¼ 1 leukaemia blast cell in 10,000
Molecular Failure/MRD-Positivity Patient in complete hematologic remission but not in molecular complete remission >0.01%
Molecular Relapse/MRD-Positivity Patient still in complete remission, had previous molecular complete remission; Leukemic blast cells in bone
marrow not detectable (<5%)
Hematologic Relapse >5% ALL cells in bone marrow/blood
Abbreviations: ALL ¼ acute lymphoblastic leukemia; MRD ¼ minimal residual disease.
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carried out as soon as possible.
Remission Induction. The goal of induction therapy is achieve-
ment of a CR and/or CMR, usually within 2 induction cycles
(approximately 16-22 weeks). Most regimens are centered on
vincristine, corticosteroids, and anthracycline (daunorubicin,
doxorubicin, idarubicin), with or without cyclophosphamide or
cytarabine. L-asparaginase is the only ALL-specific drug that de-
pletes asparagine levels and was mainly explored in pediatric trials; it
is currently used also in adults. Pegylated asparaginase significantly
increases the period of asparagine depletion. Dexamethasone is often
preferred to prednisone, because it penetrates the bloodebrain
barrier (BBB) and also acts on resting leukemic blast cells.
Two regimens are mostly used in adult ALL: one—inspired by
the pediatric Berlin-Frankfurt-Münster protocols—is often applied
in European adult ALL trials; the other is the hyper-CVAD
(cyclophosphamide, vincristine, doxorubicin, and dexamethasone),
with 2 different alternating intensive chemotherapy cycles, identical
for induction and consolidation, for a total of 8 cycles.32 It is used in
the United States, but also in other parts of the world.
Consolidation Therapy. The rationale to use systemic high-dose
(HD) therapy is to achieve a CMR and reach sanctuary sites
(CNS and testicles). Most protocols use 6 to 8 courses with HD
methotrexate (MTX) or HD cytarabine with or without
asparaginase.
Maintenance Therapy: Still a Backbone of ALL. Maintenance
therapy consists of daily 6-mercaptopurine and weekly MTX. In
some regimens, reinductions are given: in one randomized study,
the maintenance arm with reinforcement cycles was not superior toTable 4 Outcome of Adult ALL According to Age
Type of
Treatment Time Period Studies, n Patients, n
Ag
Pediatric-Inspired
for AYAs
2008-2015 6 832
Adult Trials 1998-2016 20 7961 3
Elderly Age-
Specific Protocols
1996-2016 11 653
Abbreviations: ALL ¼ acute lymphoblastic leukemia; AYA ¼ adolescents and young adults.
aWeighted mean.
Clinical Lymphoma, Myeloma & Leukemia May 2018conventional maintenance (37% vs. 38% at 8 years).33 Mainte-
nance duration of 2.5 to 3 years is recommended; its omission
worsens outcome in B-lineage ALL, but not in T-ALL,34 and is not
required in mature B-ALL.35
Age-Adapted Protocols. The outcome of ALL is strictly related to
age, with cure rates of 80% to 90% in children, and 30% in elderly/
frail ALL patients (Table 4). Therefore, age-adapted protocols have
emerged, dictated by toxicities and comorbidities. Although there is
no uniform consensus, the following age groups are considered:
 Adolescents and young adults (AYA), defined from 15 to 18 and
35 to 40 years, respectively;
 Adults, age range 35 to 40 and up to years and younger to
60 years;
 Elderly patients older than 55 to 60years; and
 Frail patients not suitable for any intensive therapy, older than
70 or 75 years.
Adolescents and Young Adults. Pediatric-inspired therapy provides
increased drug intensity, including larger cumulative doses of corti-
costeroids, vincristine, L-asparaginase, and consequent CNS-directed
therapy, with a reduced role of allo-SCT. In a meta-analysis including
11 trials and 2489 AYA patients, pediatric-inspired regimens were
superior to conventional adult chemotherapy.36 In recent studies for
AYAs,37-39 survival rates at 5 years were 67% to 78%, compared with
34% to 41% with former protocols.
Adults. In 20 studies from 1998 to 2016, including nearly 8000
adults, the weighted mean for CR rate was 84% (94%-93%) and
the 5-year OS approximately 35%. Using current approaches, the
CR rate increased to 80% to 90%, being higher for SR patients
(90%) and lower in HR patients (70%-80%). A CMR rate70%e (Range),
Years
CR Rate
(Range), %
Early Death
(Range), %a
Overall Survival
(Range), %a
27 (15-60) 93 (85-98) 5 (1-7) 70 (60-78)
2,7 (12-92) 84 (74-93) 7 (1-10) 36 (27-60)
62 (55-85) 73 13 42
Sabina Chiaretti et alcan be achieved in SR patients and approximately 50% in HR
patients.31
The OS for SR patients is 50% to 70% with chemotherapy
alone. The outcome for HR patients has also increased to approx-
imately 50% when allo-SCT in CR1 is given. Prospective adult
studies applying the same drugs and time dose-intensity, without
the term “pediatric-inspired,” achieved identical results compared
with AYAs, with survival rates of 60% to 70% or more.40-43
Elderly Patients. The incidence of ALL increases after the fifth
decade.44 Different approaches have been applied.45,46 So far,
neither a palliative treatment with CR rates of 43% (34%e53%),
an early death rate of 24% (18%e42%), and an OS of only 7
months (3e10 months), nor an intensive chemotherapy designed
for adult ALL with CR rates of 56% (40%e81%), early death rate
of 23% (6%e42%), and an OS of 14 months (3e29 months) is
optimal. The current general principle is a less intensive induction
based on corticosteroids, vincristine and asparaginase, avoiding
anthracyclines and alkylating agents, to reduce early treatment-
related death;upon induction, reduced intensive consolidation cycles
with MTX and citosine-arabinoside (ARA-C) are given. In 9 recent
prospective studies for older patients (55e81 years), with this
scheme, the CR rate was 71% (43%e90%), early death decreased
to 15% (0e36%), and OS increased to 42 months.
Treatment Approaches With Reduced Intensity. Reasons to reduce
chemotherapy intensity are the difficulty in administering intensive
regimens and allo-SCT in patients older than 50 years and the rate
of toxic deaths.
Low-intensity chemotherapy is of interest when combined with
targeted therapies (eg, with inotuzumab47), that lead to a CR rate of
98% and a 2-year progression-free survival (PFS) of 52%, or with
dasatinib.48
Acute Lymphoblastic Leukemia Subtypes
Philadelphia Chromosome-Positive ALL. Patients with Phþ ALL
constitute approximately 25% of adult B-ALL, with an increasing
incidence to approximately 50% among elderly patients. In the pre-
imatinib era, Phþ ALL was the poorest ALL subtype. The CR rates
were 60% to 70%, CMR rates <5%, and OS with chemotherapy
alone 10% and approximately 30%with allo-SCT.
The results improved substantially when the first-generation TKI
imatinib became available. CR rates increased to 80% to 90%,
CMR rate to 50%, and the 5-year survival to 50%.13
In Phþ ALL, a chemotherapy-free induction regimen, consisting
only of prednisone combined with the TKI dasatinib was applied in
prospective trials. This therapy avoids induction deaths, resulting in
a CR rate of nearly 100% and can be given without age limit,49
avoiding allo-SCT in CR1, if feasible. These patients have to be
carefully monitored and if a molecular relapse, mutation, or intol-
erability is emerging, therapy must be intensified. Also in the
EWALL (European Working Group for Adult Acute Lympho-
blastic Leukemia) studies, reduced intensive chemotherapy was
given in combination with dasatinib48 or nilotinib.50 The CR rates
were very high with >90% because of a low rate of deaths in
induction and remission.Ponatinib has been tested in a phase II single-arm trial for pre-
viously untreated Phþ ALL patients in combination with hyper-
cyclophosphamide, vincristine, doxorubicin and dexamethasone;
initially, ponatinib was given at 45 mg daily, but the study was
amended after 2 fatal myocardial events. After this modification no
further vascular events were reported. The CR, complete cytoge-
netic response (CCyR), major molecular response, and CMR rates
were 98%, 98%, 97%, and 77%, respectively; no benefit in per-
forming allo-SCT was observed.51 A phase II trial (Gruppo Italiano
Malattie EMatologiche dell'Adulto [GIMEMA] 1811) with pona-
tinib (with steroids) in newly diagnosed elderly patients resulted in
high rates of CR, CCyR, and CMR (90%, 90%, and 57%,
respectively), suggesting that ponatinib is effective also as
monotherapy.52
Is Allo-SCT Essential for Phþ ALL?. Allogeneic stem cell trans-
plantation was the only curative option for adults with Phþ ALL.
With intensive chemotherapy induction, imatinib given
throughout, and allo-SCT, the cure rate in younger patients was
50% to 60% in several trials. A prospective randomized trial in-
dicates that allo-SCT is still associated with a better recurrence-free
survival (RFS) in younger Phþ ALL patients.53 Currently, the
tendency is to reduce/replace allo-SCT in CR1 by combining
TKIs with low-dose chemotherapy or with immunotherapeutic
approaches (see Immunotherapy in Ph ALL).
The definition of a good-risk Phþ ALL patient is not established:
therefore, the scientific effort should focus on the definition of
patients who do unequivocally need transplantation. A potential
algorithm for transplantation decision-making should include
not only MRD, but also detailed genomic characterization at
diagnosis.
Finally, autologous transplantation54 might be suggested in
elderly or comorbid Phþ ALL patients who are repeatedly MRD,
and in countries where allo-SCT is limited for financial reasons.
Is Maintenance With a TKI After Allo-SCT Essential/of Benefit?.
The gold standard is to give a TKI also after allo-SCT, as supported
by a randomized study.55 However, toxicity is high for Imatinib
And Dasatinib48 and higher for nilotinib56; finally, it is not clear for
how long TKIs after allo-SCT should be given.
Is There an Optimal/Best TKI? The Issue of TKI Resistance. Faster
and deeper molecular responses are achieved with second-generation
TKIs, but it is open to what extent this transfers into a survival
benefit.
One major issue is represented by the emergence of mutations,
with T315I48,57 inducing resistance to most TKIs, with the
exception of ponatinib, which—possibly associated with chemo-
therapy—can be used as a bridge to allo-SCT; T315I-inclusive
compound mutants confer resistance also to ponatinib.58 Therefore,
for such cases, the use of alternative approaches is urgently required.
Potential compounds include the vascular endothelial growth factor
receptor inhibitor axitinib59 and ABL001 (asciminib).60
In general, mutational screening should be performed in
patients with persistent MRD or progressive disease, and the
recommendation is to switch to another TKI while screening forClinical Lymphoma, Myeloma & Leukemia May 2018 - 305
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resistance profile.
Immunotherapy in Phþ ALL. A new option in Phþ ALL is
immunotherapy.
Blinatumomab was evaluated in the phase II ALCANTARA trial
in 45 patients with R/R Phþ ALL: 36% achieved a response. The
median RFS and OS were 6.7 and 7.1 months and 7 (44%) of the
responding patients received allo-SCT.61 Blinatumomab showed a
high efficacy in patients with mutations and complex cytogenetic
aberrations of blinatumomab.61,62
Blinatumomab was also given with ponatinib to 20 patients with
R/R Phþ ALL or chronic myeloid leukemia (CML) in lymphoid
blast phase with a response rate of 65%. Median survival was 14
months.63
Blinatumomab is rapidly moving into the first-line setting, with a
3-arm randomized trial of the EWALL comparing imatinib versus
ponatinib versus ponatinib together with blinatumomab in elderly
Phþ ALL (reduced-intensity chemotherapy foreseen in all arms); the
GIMEMA 2116, on the basis of an induction of dasatinib (with
steroids) followed by a combination of dasatinib and blinatumo-
mab, is currently enrolling participants.
Inotuzumab was given with bosutinib in R/R Phþ ALL (n ¼ 14)
and CML-lymohoid blast crisis (n ¼ 2), providing an objective
response rate of 81% (CR 50%) and median event-free survival
(EFS) and OS of 8.8 months and 10.7 months, respectively.64
BCR/ABL1-Like (Ph-Like) ALL
BCR/ABL1-like (or Ph-like) ALL has been extensively charac-
terized. These cases exert a transcriptional profile similar to that of
true BCR/ABL1þ ALL, frequently harbor DIKZF1 lesions, and
CRLF2 deregulation, and can display a whole set of lesions that
involve tyrosine kinases, the most frequent being of ABL class
(ABL1, ABL2, colony stimulating factor 1 receptor [CSF1R],
platelet derived growth factor receptor alpha [PDGFRA], PDGFRB,
in approximately 10%), JAK/STAT (ie, JAK1, 2, and 3, IL7R, and
CRLF2 mutations in <10%), RAS pathway (N/K RAS, NF1,
PTPN11, and to a lesser extent FLT3), less frequently other un-
common tyrosine kinases, erythropoietin receptor gene and
MEF2D-CSF1R rearrangement. The type of lesion can vary from
case to case, making their recognition difficult; some patients do not
harbor any lesions.22,65,66
Clinically, BCR/ABL1-like ALL displays a poorer outcome in
terms of CR rate, MRD persistence, and long-term outcome.
At present, it is not clear if these cases should be treated differently
upfront or, instead, therapy switch (or intensification with allo-SCT
and targeted approaches) should be limited to cases remaining
MRDþ. Second, because of the plethora of genetic lesions, although
there is a general consensus that patients should receive a TKI, the best
TKI has not been defined. Two alternative approaches have been
proposed: the first is on the basis of the underlying lesion, including
dasatinib for cases with ABL class genes and JAK2 inhibitors,
particularly ruxolitinib, for cases with JAK/STAT pathway lesions.
This approach is not applicable in all hematologic centers; further-
more, preliminary results fromMDAnderson Cancer Center on 9 R/
R BCR/ABL1-like patients did not show significant responses.67Clinical Lymphoma, Myeloma & Leukemia May 2018Another approach could be the use of ponatinib, because in vitro
experiments showed that it is able to reduce the proliferative rate in
BCR-ABL1-like primary cells, regardless of the underlying molecular
lesions.68 Third, the role of antibody constructs, namely blinatu-
momab and inotuzumab, remain to be definitively determined.
Early T-Precursor ALL
As mentioned, ETP-ALL was recognized by gene expression and
can be easily recognized by FCM.8 ETP ALL occurs in children as
well as in adults and represents approximately 10% of T-lineage ALL.
Several genomic lesions have been identified, including mutations in
DNA methyltransferase 3 alpha, FLT3, isocitrate dehydrogenase
(NADP(þ)) 1, cytosolic, isocitrate dehydrogenase (NADP(þ)) 2,
mitochondrial, and ETV6. Interestingly, FLT3 mutations can be
detected in 35% of cases, thus implying the possibility of novel
therapeutic strategies.69 Furthermore, mutations occurring in genes
regulating cytokine receptors and RAS signaling (67%), inactivating
lesions disrupting hematopoietic development (58%), and histone-
modifying genes (48%) have been reported, suggesting that ETP-
ALL shares a similar genomic background with AML. Recent find-
ings also highlight that ETP can be further stratified according to the
levels of the homoebox A (HOXA) genes family, with the poor
outcome confined to the ETPþ/HOXAþ subgroup.70 Clinically, this
subgroupwas initially associated with a dismal prognosis. The prompt
recognition of ETP cases is improving their outcome: in fact, the use
of intensified, pediatric-inspired and MRD-driven treatments has
improved their outcome. Furthermore, the use of allo-SCT in first
CR should be considered as the optimal choice: the Group for
Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
group, in the context of GRAALL-2003 and -2005 studies, showed
a noninferior outcome of ETP patients, mostly dependent on allo-
SCT allocation.71 Finally, the presence of AML-related features
might prompt, in case of failures, to investigate the use of myeloid-
directed therapies. Alternative strategies include the use of the
BCL2, apoptosis regulator- inhibitor venetoclax, effective in
patient-derived-xenografts.72
Allogenic Stem Cell Transplantation
Allogenic stem cell transplantation was a curative approach in
adult ALL, is still the best treatment option for patients in second or
later CR, and is highly recommended for HR patients in first
CR.73,74 The outcome in MRDþ patients after induction therapy
can be improved by eradicating MRD levels: ongoing studies (eg,
with blinatumomab) are extremely promising.75
Because allo-SCT is aggravated by treatment-related mortality
(10%-20%) and impaired life quality because of chronic graft versus
host disease, there are attempts to avoid allo-SCT in first CR.
Stem Cell Donors. Different donor sources for allo-SCT are
available. There is increasing evidence that outcome is equivalent
with siblings and compatible matched unrelated donors (MUD).
Haploidentical-SCT (haplo-SCT) is being increasingly used, for
cost reasons and prompt availability of a family donor. MUD versus
haplo-SCT with an identical post-cyclophosphamide graft versus
host disease prophylaxis in a European prospective randomized trials
will be evaluated.
Table 5 Blinatumomab Activity
Parameters
PhD ALL PhL R/R ALL Positive MRD
Pivotal Phase II (ALCANTARA) Confirmatory Phase II Tower Phase III BLAST Phase II
n 45 189 271 116
CR/CRh/CRi, % 36 43 45 NA
MRD Negativity, %a 88 82 76 78
OS, median (months) 7.1 6.1 7.7 36
Abbreviations: ALL ¼ acute lymphoblastic leukemia; CRh ¼ CR with incomplete hematologic recovery; CRi ¼ complete remission with incomplete recovery; MRD ¼ minimal residual disease; OS ¼
overall survival; Ph ¼ Philadelphia chromosome; R/R ¼ relapsed/refractory.
aMinimal residual disease negativity defined according to molecular level <0.01%.
Sabina Chiaretti et alProphylaxis of CNS Leukemia
Prophylactic CNS therapy in ALL is essential to prevent not only
CNS, but also systemic relapse and includes intrethecal (MTX alone
or with ARA-C and steroids), systemic HD MTX and ARA-C, and
radiation therapy, the latter rarely used. With these modalities,
the CNS relapse rate decreased to 5% and in trials with early
HD-dose chemotherapy, CNS relapse rate was 2%.
Effective CNS prophylaxis is even more crucial in patients with
targeted therapies. In Phþ ALL, dasatinib and ponatinib cross the
BBB, whereas imatinib and nilotinib, as well as rituximab, inotu-
zumab, and blinatumomab do not.
Therapy of CNS Disease. At diagnosis, 5% to 10% of adult pa-
tients have CNS leukemia, with a prevalence in mature B-ALL and
T-ALL (10%-15% and 10%, respectively). In MLL-r cases, NG2
expression correlates with CNS involvement. For CNS leukemia at
diagnosis, intrethecal chemotherapy is given 2 to 3 times/week, over
2 to 3 weeks until 2 consecutive cerebrospinal fluid (CSF) exami-
nations are blast-free. If adult ALL patients with initial CNS
involvement are treated adequately, they have no inferior outcome
with regard to leukemia-free survival or CNS relapse rate and CNS
involvement is no longer an adverse prognostic factor.
Relapse in the CNS is difficult to treat: in most cases, a bone
marrow involvement is detected. Treatment consists of intrethecal
chemotherapy, radiotherapy, and systemic therapy, the outcome is
dismal and allo-SCT was the best option. CAR T-cells represent aTable 6 Inotuzumab Activity
Parameter
Single Dose
Phase II
Weekly Dose
Phase II
Weekly Do
Multicente
Phase II
n 49 41 35
Dose/Schedule 1.8 mg/m2 day 1,
every 3-4 weeks
0.8 mg/m2
day 1, 0.5 mg/m2
days 8, 15
0.8 mg/m2
day 1, 0.5 mg
days 8, 15
Results
ORR (%) 57 59 68
CR (%) 18 20 31
MRD negativity
(FCM, %)
68 71 84
Median Survival, ms 5 7.3 7.4
Abbreviations: ALL ¼ acute lymphoblastic leukemia; FCM ¼ flow cytometry; INO ¼ inotuzumab ozpromising option: a leptomeningeal infiltration was successfully
treated with this approach and CAR T-cells detected in the CSF.76
Immunotherapy
Anti-CD19 Bi-Specific T-Cell Engager: Blinatumomab. CD19,
virtually expressed on all B-ALL blasts, is an ideal target for
antibody-directed therapy. Blinatumomab, the first bispecific T-cell
engaging antibody construct, redirects host CD3þ T cells to
CD19þ ALL cells.77
Minimal Residual Disease. Blinatumomab was first assessed in the
MRD setting. Topp et al, used blinatumomab in 116 patients with
ALL in first or later MRDþ CR.78 Seventy-eight patients achieved
MRD negativity after 1 cycle and 80% after 4. With a median follow-
up of 29 months, the median survival was 36 months and median
RFS months.75 Notably, allo-SCT did not confer a survival benefit.
Relapsed/Refractory ALL. In the confirmatory phase II study of 189
heavily pretreated patients with R/R Ph ALL, blinatumomab was
associated with a CR/CR with incomplete hematologic recovery rate
of 43%. The median response duration was 9 months and median
survival 6 months.79 A phase III randomized trial (TOWER study)
compared blinatumomab (n ¼ 271) with an investigator’s choice
chemotherapy (standard of care [SOC]; n ¼ 134). The overall
response rate was 45% with blinatumomab versus 30% with SOC,
and CMR among responders 75% and 48%, respectively. These
r INO-VATE
Phase III
INO With Mini-
HCVD R/R ALL
INO With Mini-
HCVD First-Line,
Elderly
109 70 52
/m2
0.8 mg/m2
day 1, 0.5 mg/m2
days 8, 15
1.3-1.8 mg/m2 in cycle
1, 1.0-1.3 mg/m2 in
cycles 2-4
1.3-1.8 mg/m2 in cycle
1, 1.0-1.3 mg/m2 in
cycles 2-4
88 77 97
36 59 80
78 81 96
7.7 11 Not reached
ogamicin; MRD ¼ minimal residual disease; R/R ¼ relapsed/refractory.
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308 -median survival was 7.7 and 4.0 months with blinatumomab versus
SOC, respectively, with better results in salvage 1 patients (Table 5).80
Toxicity consists of fever, and chills—due to a cytokine release
syndrome (CRS), and hypogammaglobulinemia. Tremor, headache,
other mental status changes, and rarely seizures were reported.
Serious adverse events are uncommon, and include encephalopathy.
Inotuzumab Ozogamicin
CD22 is expressed in 95% B-ALL and universally in Burkitt
leukemia. Inotuzumab ozogamicin comprises an anti-CD22 anti-
body linked to calicheamicin.81 In a single institution phase II study
including 49 patients with R/R ALL, inotuzumab was administered
at a starting dose of 1.3 to 1.8 mg/m2 intravenously every 3 to 4
weeks.82 The objective response rate was 57%, and median survival
5.1 months; nearly half of the patients treated proceeded to allo-
SCT. Common adverse effects included fever and hypotension.
Serious toxicities included veno-occlusive disease (VOD) post allo-
SCT (23%), mainly observed in older patients receiving double
alkylators during conditioning. To minimize toxicities, inotuzumab
was administered on a different schedule in 40 R/R ALL patients,83
resulting in similar responses (59%), fewer adverse events, and lower
rates of VOD. Similar results were reported in a multicenter phase
II trial.84
Finally, in a randomized phase III trial comparing inotuzumab
with SOC in R/R ALL (salvage 1 and 2), objective response rates
were 88% (CR 81%) with inotuzumab and 32% (CR 29%) with
SOC. Among responders, the MRD-negativity rates were 78% and
28%, respectively. The median PFS was 5.0 with inotuzumab
versus 1.8 months with SOC, median survival was 7.7 versus 6.7
months and 2-year survival was 23% versus 10%.85
Combination Therapy in R/R ALL
Inotuzumab was evaluated in the R/R setting in combination
“mini-hyper-ìcyclophosphamide, vincristine and dexamethasone
(CVD)”: 59 patients were treated, leading to objective response in
78% (CR 59%), with 82% of responders achieving MRD nega-
tivity. The 2-year PFS and OS rates were 60% and 32%, respec-
tively; better results were observed in salvage 1 patients. The survival
of patients treated with mini-hyper-CVD with inotuzumab were
superior to a historical cohort treated with inotuzumab mono-
therapy (median survival, 11 months vs. 6 months).86 Studies
exploring lower doses of inotuzumab are ongoing (Table 6).
Other Agents in Development
Other antibody drug conjugates (ADC) targeting CD19 and
CD22 are in development. Among them, anti-CD19 PBD-conjugate
(ADCT-402) is an ADC composed of a humanized monoclonal
antibody directed against human CD19, conjugated to SG3199, a
pyrrolobenzodiazepine dimer cytotoxin.87 In a phase I study in 29 R/
R ALL patients, ADCT-402 was well tolerated. Four patients
responded at the higher-dose levels (3 CR, 1 complete remission with
incomplete recovery [CRi]), 2 achieving MRD negativity.
Chimeric Antigen Receptor T-Cell Therapies
Chimeric antigen receptor T-cells are a recent development in
cancer treatment.88 CAR T cells directed at CD19 are effective forClinical Lymphoma, Myeloma & Leukemia May 2018patients with aggressive B-cell lymphomas and pediatric ALL. In the
initial study, 59 children with R/R ALL were treated.89 The CR rate
was 93%. The estimated 1-year EFS and OS were 55% and 79%,
respectively. CRS occurred in 88% of patients, all of whom
recovered. In a confirmatory phase I/II, 25-center, global study, 75
patients aged 3 to 23 years (median age, 11 years) were treated.90
The overall remission rate within 3 months was 59% (83%
among patients who were evaluable for efficacy). All responders
achieved negative MRD status. The EFS and OS rates were 50%
and 76% at 12 months, respectively.
In the ZUMA-3 study, 33 patients with R/R ALL were treated.
The overall response rate was 71% (CR 67% and CRi 4%).91
Overall, the rate of Grade 3 CRS was 28%; and any Grade 3
neurologic events was 52%.
Recently, an adult study of CD19 CAR T-cells was reported.92
Eighty-three patients were enrolled, 78 underwent apheresis and
53 were treated. CR was observed in 44 of 53 patients treated (83%;
CR in 44 of 78 who underwent apheresis ¼ 56%). Median EFS was
6.1 months and median survival was 12.9 months for the patients
treated. The 2-year EFS and survival rates were approximately 15%
and <30%, respectively. Patients with marrow blasts <5% had
longer EFS and survival durations, and lower incidences of CRS and
neurotoxic events.
To circumvent CD19 escape after CD19-CAR T-cell therapy,
CD22-targeted CAR T-cell therapy has recently been developed.93
Of the 15 children and adults with R/R B-ALL, most who were
previously treated with CD-19 directed immunotherapy, 11 (73%)
achieved CR after treatment with 1  106/kg. Current CAR
T-cell therapies use autologous lymphocytes, which can be trou-
blesome: new platforms provide an “off-the-shelf” approach, derived
from healthy volunteer donors. Preliminary results of the CALM
study using this therapy in a phase I dose-escalation trial showed
that in 6 adults, 4 achieved CRi with MRD negativity.93 Off-the-
shelf products targeting CD22 and allogeneic cord blood-derived
natural killer cells are being developed.
Concluding Key Points
 The treatment of ALL still relies on the use of chemotherapy,
with survival rates ranging from 50% to 70% in AYA.
 Risk stratification relies on MRD, and must be integrated with
the genetic profile.
 Targeted treatment (TKI, and immunotherapy) are opening a
new era in ALL.
 Philadelphia chromosome-positive ALL long-term outcome
improved from 10% to 60% in recent years, and is likely to
improve even further
 Allogeneic SCT recommendation must be reconsidered in light
of all these key points.Acknowledgments
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